Clinical Trials Browser

Phase 3 × spartalizumab × Clear all

NCT07277842 2025-12-11

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Locally Advanced Low Rectal Adenocarcinoma

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

NCT05751928 2025-07-08

NEO-MIMAJOR

Phase 3 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT06507371 2025-06-26

mRCAT-III

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06794086 2025-05-13

SPARKLE-L

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04557020 2024-05-01

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Phase 3 Unknown

Nasopharyngeal Carcinoma

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3 Withdrawn

Uterine Cervical Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

HER2+ Breast Cancer

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT04084626 2022-01-05

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

Phase 3 Unknown

Epstein-Barr Virus Infections

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT04711434 2021-01-20

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Phase 3 Unknown

Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis

NCT03744247 2019-05-02

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Phase 3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT03791918 2019-05-02

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Phase 3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular